Ipamorelin vs Thymosin Beta-4
Well Studied vs Well Studied
synergistic Mechanism-based · 47% Ipamorelin and Thymosin Beta-4 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ipamorelin Thymosin Beta-4
Weight 711.85 Da 4,963.44 Da
Half-life ~2 hours Dose-dependent; relatively short (exact values not established)
Chain 5 amino acids 43 amino acids
Type Growth hormone secretagogue Thymosin peptide
Key Benefits
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Thymosin Beta-4
01 Systemic regenerative effects
02 Proven clinical efficacy
03 Optimal bioavailability for tissue repair
04 Promotes angiogenesis
05 Reduces inflammation
Dosing Protocols
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Thymosin Beta-4
2-6mg per injection (varies by protocol and severity) / Daily for acute healing, 2x weekly for maintenance/chronic conditions
Acute Wound Healing 1.6mg Daily
Cardiac Protection 42mg Single dose
Chronic Tissue Repair 6mg Twice weekly
Neurological Recovery 30mg Three times over 72 hours
General Regeneration 2-5mg Daily or every other day
Side Effects
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Thymosin Beta-4
Mild injection site reactions
Local inflammation at injection sites
Contraindications
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Active chemotherapy treatment
Severe systemic allergies to peptides
Research Evidence
Ipamorelin Thymosin Beta-4
Status Well Studied Well Studied
References 5 studies 4 studies
Latest October 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.